Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Robo.ai is trying to move from a failed smart-EV revenue base into an AI robotics, intelligent hardware and asset platform. The filings show FY2025 revenue of only $0.95 million, a $167.3 million net loss, $4.1 million of cash, $124.6 million of liabilities, n
OpenAI Infrastructure Acquisition Corp. is a newly public SPAC with $140.5 million in trust, $1.1 million of cash outside trust, no operating revenue, no announced target and an April 6, 2027 deadline. The current thesis is trust math, sponsor incentives and futur
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenForafric owns real Morocco and West Africa milling assets, but the current stock story is a very-high-risk turnaround: H1 revenue collapsed, the 2025 annual report is late, going-concern language is live, and the newest strategic pivot needs hard proof.
OpenADM enters 2026 with raised guidance, stronger ethanol and Nutrition signals, and deep liquidity, but the first-time read has to balance those positives against weak 2025 segment profit, commodity timing, trade exposure, and still-live litigation.
Open